P05. Predictive factors of early and late mortality and evaluation of therapeutic efficacy in patients with bacteremia associated with MDR Acinetobacter baumannii: the Itaca (Italian advances on carbapenem-resistant Acinetobacter) study
Abstract
Abstract Background Carbapenem-resistant Acinetobacter baumannii (CRAB) infection, especially bacteremia, represents a major challenge for clinicians due to high morbidity and mortality rates. Methods This is an observational, prospective, multicenter study conducted in 52 Italian centers for 18 months in hospitalized patients who developed clinically significant infection and concomitant bacteremia with CRAB. Patients aged >18 years with microbiological isolates from CRAB blood cultures, who developed a clinical syndrome in the absence of other isolates, and who received targeted antibiotic therapy for at least 24 hours were enrolled. The primary objective of the study was the analysis of factors that could predict mortality at 14 and 30 days after the development of infection. Results During study period, 398 patients were enrolled. Out of these, 140 (35.2%) were male, the mean age was 67 years, and the mean Charlson Comorbidity Index was 5 points. The source of bacteremia was primary in 34.8% of patients, CVC-related in 19.1%, secondary to hospital-acquired pneumonia in 23.6% and ventilator-associated pneumonia in 22.5%. Other sources were intra-abdominal, urinary or skin and soft tissue infection. Overall, 89/398 (22.3%) died at 14 days and 107/398 (26.8%) at 30 days. At univariate analysis, follow-up blood cultures were more frequently negative in survivors (75.3%) compared to non survivors (48%) at 14 days (P = 0.008); cefiderocol containing-regimen was associated with…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.